Wockhardt Limited posts strong FY 26 financials

Financial Highlights

Wockhardt Limited, the pharmaceutical and biotechnology major, reported its 4th Quarter Results for Financial Year 2025-26 today. The company posted a profit before tax (PBT) of Rs. 238 crore for FY26 compared to a loss of Rs. 16 crore in the previous year. The revenue for Q4FY26 stood at Rs. 965 crore, marking a 30% growth compared to Rs. 743 crore in the previous year. The EBITDA for Q4FY26 was Rs. 196 crore, showing a 147% increase compared to Rs. 79 crore in the previous year.

Biotech Segment Performance

The biotech operations for the quarter stood at Rs. 252 crore, recording a growth of 126% versus Q4FY25. On a full-year basis, the biotech operations recorded 27% growth, delivering Rs. 697 crore. This robust achievement is fueled by our emerging market biotech segment growing at >34% on FY25 with accelerated business opportunities and strategic business partnerships.

Regional Revenue Highlights

The India branded business stood at Rs. 112 crore in Q4FY26 with a growth of 18% compared to the previous year. The UK region stood at Rs. 349 crore in Q4FY26 with a growth of 20% compared to the previous year. The emerging markets region stood at Rs. 320 crore in Q4FY26 with a growth of 124% compared to the previous year.

New Product Launches

Wockhardt Limited has launched several new products. The company has completed Phase 3 clinical trials successfully for five novel antibiotics: Emrok®, Emrok O®, Miqnaf®, Zaynich®, and Foviscu®. Miqnaf® has been approved and launched in India. EMROK®/ EMROK O® continues to address critical unmet needs in the market.

Looking ahead, Wockhardt Limited is poised for continued growth with its strong financial performance and strategic product launches.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Wockhardt Limited

Wockhardt Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Wockhardt moves sideways over three months, with neither buyers nor sellers taking control. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue contracts at -3.2% CAGR. That signals structural headwinds, not a short-term blip. The stock holds at 40% of its 52-week range with RSI at 56. In other words, neither side has a clear edge right now. Price climbs recently despite -3.2% revenue growth and a PEG of 99.00. Consequently, either institutions position ahead of improvement or the move fades when earnings disappoint. Treat this as a trading signal, not an investment thesis.